FULC Slate Reverse Merger: $245M Migraine Play

Fulcrum Therapeutics (Nasdaq: FULC) is reverse-merging with Slate Medicines, a private migraine biotech, in an all-stock deal that hands Slate’s anti-PACAP/VIP pipeline a Nasdaq listing. The combined company will keep the Slate Medicines name and trade under the ticker SLTE, backed by an oversubscribed $245 million private placement. Fulcrum shares closed at $3.86 on the news.

The structure echoes the Fibrx reverse merger earlier this month: a cash-constrained public shell hands its listing to a private company with a hotter pipeline. Pre-merger Fulcrum holders will own roughly 5% of the combined entity, Slate holders 95%. Fulcrum contributes about $20.3 million in cash and pays a dividend of roughly $270 million to its shareholders ahead of closing, effectively returning most of its remaining capital.

Slate’s lead asset is SLTE-1009, a clinical-stage subcutaneous monoclonal antibody that binds both PACAP and VIP, two neuropeptides central to migraine. Slate argues a single antibody that blocks both targets should beat PACAP-only drugs on efficacy. The candidate, licensed from China’s DartsBio, was engineered for half-life extension to allow subcutaneous dosing and potential quarterly administration. Slate emerged from stealth in February 2026 with a $130 million Series A led by RA Capital, Forbion, and Foresite, and is led by CEO Gregory Oakes.

The $245 million PIPE, led by Frazier Life Sciences with Forbion, RA Capital, Deep Track, Foresite, OrbiMed, RTW, and Mingxin, is expected to fund operations into 2029 through a Phase 1 healthy-volunteer study and a Phase 2 dose-ranging trial in migraine patients, planned for the second half of 2027. The cash covers an ambitious jump: Slate is still pre-data, so the money has to carry the asset from healthy volunteers through proof of concept.

The market is big but competitive. CGRP-blocking migraine drugs generated about $5 billion in 2025 sales, and Lundbeck’s anti-PACAP antibody bocunebart already posted positive Phase 2b data in June. Eli Lilly’s anti-PACAP program failed and was scrapped, a reminder that PACAP-only targeting is not a sure thing. Slate’s pitch is that blocking both PACAP and VIP, plus a quarterly dosing schedule, improves on what CGRP drugs already deliver.

For Fulcrum, this is the exit after it discontinued its sickle cell drug pociredir and began exploring strategic alternatives in June. The risk is familiar: SLTE-1009 has no clinical data yet, and investors are being asked to pay for a dual-target thesis against a class with a mixed record. Watch the SLTE debut at deal close and the Phase 2 readout in H2 2027.

Source: Fulcrum–Slate Medicines merger press release

What It Means for the Trade

The structure tells you what happened: Fulcrum holders keep roughly 5% of the combined company and receive a roughly $270 million dividend — that is a controlled liquidation, not a merger. Fulcrum’s sickle cell program was dead, the cash was going nowhere, and the board chose to hand the listing to a venture-backed migraine biotech rather than burn it down slowly. Fulcrum at $3.86 is mostly the right to a $245 million PIPE-funded shell debuting as SLTE. If you own FULC into the close, you are making two trades at once: the dividend arbitrage and a forced conversion into a pre-data PACAP/VIP migraine bet. Decide which one you meant to hold.

For Slate, the deal is excellent. An oversubscribed $245 million PIPE funds operations into 2029 — through the Phase 1 and the Phase 2 dose-ranging trial planned for H2 2027. That is enough runway to reach proof of concept without returning to the market, which is the whole point of taking a listing through a cash-rich shell rather than a conventional IPO in a soft window.

Mechanism and Market Context

The science pitch is dual-target breadth. PACAP and VIP are related neuropeptides in the calcitonin-family signaling that migraine drugs have not yet industrialized the way CGRP was industrialized. The CGRP class — Aimovig, Emgality, Ajovy, Nurtec, and the rest — generated about $5 billion in 2025 and works well for many patients, but a substantial minority does not respond. Anti-PACAP is the field’s leading next wave: Lundbeck’s bocunebart posted positive Phase 2b data in June, which is the datapoint the whole Slate thesis hangs on. SLTE-1009’s differentiation is blocking both PACAP and VIP with one half-life-extended antibody, dosed subcutaneously with potential quarterly administration.

Skepticism is warranted on two counts. Eli Lilly’s anti-PACAP program failed and was scrapped — the target has already claimed one major casualty, so “PACAP-only is not a sure thing” is established fact, and Slate’s answer (add VIP) is a hypothesis, not evidence. And the asset was licensed from China’s DartsBio, which means the originating science was built elsewhere and the western rights carry the usual regional-data questions if regulators ask. Everything rests on the H2 2027 Phase 2.

Risks and What Could Go Wrong

1. No clinical data exists. SLTE-1009 has not yet been through healthy volunteers; the pre-Phase 2 base rate in migraine is poor, and the dual-target mechanism is unproven in humans.
2. Mechanism competition. Bocunebart is ahead with Phase 2b data; if it converts, Slate is second-to-market with a less validated construct.
3. Shell mechanics. Reverse-merger debuts are volatile; the 5% Fulcrum stub trades on technicals until the SLTE ticker establishes its own holder base. If you trade this, trade it as the Phase 2 option with two years of runway, and do not confuse the PIPE’s conviction with clinical evidence.